Linked Data API

Show Search Form

Search Results

1137416
registered interest false more like this
date less than 2019-07-08more like thismore than 2019-07-08
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Accelerated Access Collaborative remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will list (a) the criteria and (b) the timelines for products to be considered in (i) the current and (ii) future review rounds of the Accelerated Access Collaborative. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 274540 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-15more like thismore than 2019-07-15
answer text <p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.</p><p>The AAC will consider the following areas of interest when determining which products to support:</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p> </p><p> </p><p> </p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-07-15T15:23:36.753Zmore like thismore than 2019-07-15T15:23:36.753Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon remove filter
1137418
registered interest false more like this
date less than 2019-07-08more like thismore than 2019-07-08
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Accelerated Access Collaborative remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what criteria the Accelerated Access Collaborative uses in relation to decision-making on (a) medicines, (b) diagnostic tools and (c) digital services. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 274542 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-15more like thismore than 2019-07-15
answer text <p>The Accelerated Access Collaborative (AAC) is interested in supporting the most strategically important products that will have the biggest impact on patient health outcomes and delivery of National Health Service services.</p><p>When selecting products, the AAC will consider the following irrespective of innovation type (i.e. medicines, diagnostic tools, and digital products):</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p>Further information is available at the following link:</p><p><a href="https://www.nice.org.uk/aac" target="_blank">https://www.nice.org.uk/aac</a></p><p> </p><p> </p> more like this
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-07-15T15:33:03.587Zmore like thismore than 2019-07-15T15:33:03.587Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon remove filter
1134018
registered interest false more like this
date less than 2019-06-24more like thismore than 2019-06-24
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Accelerated Access Collaborative remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, if he will list the (a) criteria and (b) timelines for products to be considered in (i) the current round and (ii) future review rounds of the Accelerated Access Collaborative route. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 268506 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-02more like thismore than 2019-07-02
answer text <p>In October 2018, the Accelerated Access Collaborative (AAC) announced it was supporting the uptake of 12 high performing products, with the potential to improve the lives of up to 500,000 patients per year and save the National Health Service £30 million per year in England. All the products currently being supported by the AAC have been recommended by the National Institute for Health and Care Excellence, and therefore evidence on clinical benefits and cost savings were considered as part of the process.</p><p>The AAC board met on 26 June and had a positive discussion about future products and expects to announce further products later this year.</p><p>The AAC will consider the following areas of interest when determining which products to support:</p><p>- evidence of clinical and cost effectiveness;</p><p>- addressing significant unmet need;</p><p>- application to large populations or high budget impact; and</p><p>- enabling a novel mode of action or enabling significant changes to the care pathway.</p><p> </p><p> </p>
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-07-02T16:12:14.213Zmore like thisremove minimum value filter
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon remove filter
1134021
registered interest false more like this
date less than 2019-06-24more like thismore than 2019-06-24
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Accelerated Access Collaborative remove filter
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what plans the Accelerated Access Collaborative has to prioritise products which help control hospital-acquired infections. more like this
tabling member constituency Strangford more like this
tabling member printed
Jim Shannon remove filter
uin 268509 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-02more like thismore than 2019-07-02
answer text <p>The Accelerated Access Collaborative (AAC) is interested in identifying and supporting strategically important products that will have the biggest impact on patient health outcomes and/or the delivery of NHS services. This may include those which help control hospital-acquired infections.</p><p>The AAC has already had made significant progress towards getting the best innovations to patients quicker and at a better cost for the National Health Service.</p><p>Since 2018, NHS England has been supporting SecurAcath and Plus Sutures, products designed to reduce infection rates, on the Innovation and Technology Payment programme. SecurAcath is a device to secure catheters that reduces the infection risk for patients with a peripherally inserted central catheter and has benefited over 80,000 patients. Seven trusts with higher than 4% surgical site infection rates have adopted Plus Sutures, a triclosan coated suture, with more trusts to be supported this year.</p><p> </p> more like this
answering member constituency Gosport more like this
answering member printed Caroline Dinenage remove filter
question first answered
less than 2019-07-02T16:12:48.417Zmore like thismore than 2019-07-02T16:12:48.417Z
answering member
4008
label Biography information for Dame Caroline Dinenage more like this
tabling member
4131
label Biography information for Jim Shannon remove filter